AbCellera Biologics (ABCL) Intangibles (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Intangibles came in at $37.5 million in Q1 2026, down 9.06% YoY from $41.2 million in Q1 2025, and down 2.4% on a QoQ basis from $38.4 million in Q4 2025.
AbCellera Biologics (ABCL) Intangibles (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Intangibles data on file, last reported at $37.5 million in Q1 2026.
- Quarterly Intangibles fell 9.06% year-over-year to $37.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.5 million (down 9.06% YoY) and the FY2025 annual result came in at $38.4 million, down 8.86% from the prior year.
- Intangibles fell to $37.5 million in Q1 2026, from $38.4 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $161.0 million in Q1 2022 to a low of $37.5 million in Q1 2026.
- A 5-year average of $92.6 million and a median of $118.7 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles soared 1063.73% — and 2025, when it slumped 65.31%.
- Tracing ABCL's Intangibles over 5 years: stood at $131.5 million in 2022, then decreased by 8.42% to $120.4 million in 2023, then plunged by 65.03% to $42.1 million in 2024, then slipped by 8.86% to $38.4 million in 2025, then slipped by 2.4% to $37.5 million in 2026.
- The last three Intangibles figures came in at $37.5 million (Q1 2026), $38.4 million (Q4 2025), and $39.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 36.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.53 Mn |
| Mar 31, 2026 | 37.46 Mn |
| Dec 31, 2025 | 38.38 Mn |
| Sep 30, 2025 | 39.32 Mn |
| Jun 30, 2025 | 40.26 Mn |
| Mar 31, 2025 | 41.19 Mn |
| Dec 31, 2024 | 42.11 Mn |
| Sep 30, 2024 | 52.58 Mn |
| Jun 30, 2024 | 85.66 Mn |
| Mar 31, 2024 | 118.74 Mn |
| Dec 31, 2023 | 120.43 Mn |
| Sep 30, 2023 | 124.08 Mn |
| Jun 30, 2023 | 126.75 Mn |
| Mar 31, 2023 | 128.85 Mn |
| Dec 31, 2022 | 131.50 Mn |
| Sep 30, 2022 | 142.55 Mn |
| Jun 30, 2022 | 143.18 Mn |
| Mar 31, 2022 | 160.97 Mn |
| Dec 31, 2021 | 11.30 Mn |
| Sep 30, 2021 | 158.77 Mn |